The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.

ABSTRACT:

Purpose

The American College of Medical Genetics and Genomics (ACMG) recommended that clinical laboratories performing next-generation sequencing analyze and return pathogenic variants for 56 specific genes it considered medically actionable. Our objective was to evaluate the clinical and economic impact of returning these results.

Methods

We developed a decision-analytic policy model to project the quality-adjusted life-years and lifetime costs associated with returning ACMG-recommended incidental findings in three hypothetical cohorts of 10,000 patients.

Results

Returning incidental findings to cardiomyopathy patients, colorectal cancer patients, or healthy individuals would increase costs by $896,000, $2.9 million, and $3.9 million, respectively, and would increase

SUBMITTER: Bennette CS 

PROVIDER: S-EPMC4430464 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature